Janssen Ad26.COV2.S COVID-19 vaccine: Interim guidance and more

This interim guidance has been developed based on the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its 15 March 2021 extraordinary meeting for the Janssen Ad26.COV2.S COVID-19 vaccine

More information:

Janssen Ad26.COV2-S: Vaccine Explainer